mobocertinib succinate

mobocertinib succinate (EXKIVITY) is an FDA-listed pharmaceutical active ingredient. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

EXKIVITY is a marketed brand name for mobocertinib succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

mobocertinib succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.